Pharvaris N.V. (NASDAQ:PHVS) Stock Has Average Price Target of $59.53 According to Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $59.53.

PHVS has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, October 15th. Royal Bank Of Canada lifted their price target on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Oppenheimer reiterated an “outperform” rating on shares of Pharvaris in a research note on Friday, October 23rd. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Guggenheim increased their price objective on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th.

Pharvaris Trading Down 0.1%

Shares of PHVS opened at $33.53 on Friday. The stock has a market cap of $2.19 billion, a P/E ratio of -10.99 and a beta of -2.46. The company has a 50-day moving average of $33.66 and a two-hundred day moving average of $30.96. Pharvaris has a 12-month low of $21.02 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, analysts forecast that Pharvaris will post -3.12 EPS for the current fiscal year.

Insider Activity at Pharvaris

In other news, CFO David W. Nassif sold 6,000 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $36.47, for a total value of $218,820.00. Following the sale, the chief financial officer owned 114,300 shares in the company, valued at approximately $4,168,521. This represents a 4.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Peng Lu sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $3,500,000.00. Following the sale, the president owned 64,953 shares in the company, valued at $2,273,355. The trade was a 60.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 513,102 shares of company stock valued at $18,643,666. 11.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently modified their holdings of the company. venBio Partners LLC acquired a new position in Pharvaris during the 2nd quarter valued at about $160,569,809. 5AM Venture Management LLC bought a new stake in shares of Pharvaris during the 2nd quarter worth about $27,581,008. BlackRock Inc. acquired a new stake in shares of Pharvaris in the 2nd quarter worth approximately $26,677,000. Elmind Capital LP acquired a new stake in shares of Pharvaris in the 2nd quarter worth approximately $18,180,435. Finally, Seven Fleet Capital Management LP lifted its stake in shares of Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the period.

About Pharvaris

Pharvaris N.V. (NASDAQ: PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris’ lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.